Skip to main content
SpringerLink
Log in

Molecular Dissection of the Prostate Cancer Genome

  • Chapter
Prostate Cancer

Abstract

Prostate cancer (CaP) is the most common solid malignant tumor in American males [88]. The wide spectrum of biologic behavior [116] exhibited by prostatic neoplasms poses the difficulty of predicting the clinical course in the individual patient [73, 80]. Because of increasing public awareness and screening efforts, the enhanced incidence has translated into a large increase in the use of radical prostatectomy as well as four other treatment modalities for localized disease [89]. With this huge rise in surgical intervention, a frustrating realization of the inability to predict organ-confined disease and clinical outcome for a given patient [89,119] has emerged. Traditional prognostic markers such as grade, clinical stage, and pretreatment prostate-specific antigen (PSA) are of limited prognostic value for individual men. There is clearly a need to recognize and develop molecular and genetic biomarkers to improve both the prognosis and the management of the patient with clinically localized CaP. As with other common human neoplasms [120], the search for molecular genetic markers to better define the genesis and progression of CaP is the key focus for cancer research investigations worldwide.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Apakama I, Robinson MC, Walter NM, Charlton RG, Royd JA, Fuller CE, Neal DE, Hamdy FC (1996) bcl-2 overexpression combined with p53 accumulation correlates with hormone refractory prostate cancer. Br J Cancer 74:1258–1262

    Article  PubMed  CAS  Google Scholar 

  2. Arai Y, Yoskiki T, Yoshida O (1997) c-erbB-2oncoprotein: a potential biomarker of advanced prostate cancer. Prostate 30:195–201

    Article  PubMed  CAS  Google Scholar 

  3. Asgari K, Sesterhenn IA, McLeod DG, Cowan K, Moul JW, Seth P, Srivastava S (1997) Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. Int J Cancer 71:377–382

    Article  PubMed  CAS  Google Scholar 

  4. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. (1995) p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res 1:1295–1300

    PubMed  CAS  Google Scholar 

  5. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. (1996) Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients. J Urol 156:1511–1516

    Article  PubMed  CAS  Google Scholar 

  6. Berner A, Harvei S, Treti S, Fossa SD, Nesland JM. (1994) Prostate carcinoma: a multivariate analysis of prognostic factors. Br J Cancer 69:924–930

    Article  PubMed  CAS  Google Scholar 

  7. Berry R, Schroeder JJ, French AJ, McDonnell SK, Peterson BJ, Cunningham JM, Thibodeau SN, Schaid DJ. (2000) Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 67:82–91

    Article  PubMed  CAS  Google Scholar 

  8. Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wohr G, et al (1998) Predisposing gene for early onset prostate cancer, localized on chromosome 42.2–43. Am J Hum Genet 62:1416–1424

    Article  PubMed  CAS  Google Scholar 

  9. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Young P, Norton CR, Gridley T, Cardiff RD, Cunha GR, Abate-shen C, Shen MM (1999) Roles of NKX3.1 in prostate development and cancer. Genes Dev 13:966–977

    Article  PubMed  CAS  Google Scholar 

  10. Bookstein R, Rio P, Madreperla SA, Hong F, et al (1990) Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci 87: 7762–7766

    Article  PubMed  CAS  Google Scholar 

  11. Bookstein R, Shew JY, Chen PL, Scully P, Lee WH. (1990) Suppression of tumorgenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712–715

    Article  PubMed  CAS  Google Scholar 

  12. Bookstein R, MacGrogan D, Hisenbeck SG, Sharkey F, Allred DC. (1993) p53 mutated in a subset of advanced stage prostate cancers. Cancer Res 53:3369–3373

    PubMed  CAS  Google Scholar 

  13. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC, et al (1993) Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 53:3869–3873

    PubMed  CAS  Google Scholar 

  14. Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, Gasser TC, Koivisto P, Lack EE, Kononen J, Kallioniemi OP, Gelmann EP. (2000) Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 60:6111–6115

    PubMed  CAS  Google Scholar 

  15. Brooks JD, Bova GS, Isaacs WB (1995) Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinoma. Prostate 26:35–39

    Article  PubMed  CAS  Google Scholar 

  16. Bussemakers MJH, Van Bokhoven A, Verhaegh GW, Smitt FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB. (1999) DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59:5975–5979

    PubMed  CAS  Google Scholar 

  17. Cantley LC, Neel BG. (1999) New insights into tumor suppresssion: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96:4240–4245

    Article  PubMed  CAS  Google Scholar 

  18. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D (1997) Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57:4997–5000

    PubMed  CAS  Google Scholar 

  19. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB (1990) Allelic loss of chromosomes i6q and loq in human prostate cancer. Proc Natl Acad Sci USA 87:8751–8755

    Article  PubMed  CAS  Google Scholar 

  20. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Issacs WB, Walsh PC (1993) Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150:797–802

    PubMed  CAS  Google Scholar 

  21. Chan JM, Stampter MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M (1998) Plasma insulin-like growth factor-i and prostate cancer risk: a prospective study. Science 279:563–566

    Article  PubMed  CAS  Google Scholar 

  22. Cher ML, MacGrogan D, Bookstein R, Brown JA, et al (1994) Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer 11:153–162

    Article  PubMed  CAS  Google Scholar 

  23. Cher ML, Ito T, Weidner N, Carroll PR, Jensen RH. (1995) Mapping of regions of physical deletion on chromosome i6q in prostate cancer cells by fluorescence in situ hybridization (FISH). J Urol 153:249–254

    Article  PubMed  CAS  Google Scholar 

  24. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PA, Pinn SS, Epstein JL, Isaacs WB, Jensen RH. (1996) Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allotyping. Cancer Res 56:3091–3102

    PubMed  CAS  Google Scholar 

  25. Chi S-G, deVere White R, Meyers FJ, Siders DB, Lee F, Gumerlock PH. (1994) p53 in prostate cancer: frequent expression transition mutations. J Natl Cancer Inst 86:926–933

    Article  PubMed  CAS  Google Scholar 

  26. Coffey DS. (1992) The molecular biology, endocrinology and physiology of the prostate and seminal vesicle. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED Jr (eds) Campbell’s urology, vol 1. Saunders, Philadelphia, pp 221–266

    Google Scholar 

  27. Cooney KA, Wetzel JC, Consolino CM, Wojno KJ. (1996) Identification and characterization of proximal 6q deletions in prostate cancer. Cancer Res 56:4150–4153

    PubMed  CAS  Google Scholar 

  28. Cooney KA, McCarthy JD, Lange E, Huang L, Miefeldt S, Montie JE, Oesterling JE, Sandler HM, Lange K (1997) Prostate cancer susceptibility locus on chromosome lq: a confirmatory study. J Natl Cancer Inst 89:955–959

    Article  PubMed  CAS  Google Scholar 

  29. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein A, Davis MA, Goodman PJ. (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419–424

    Article  PubMed  CAS  Google Scholar 

  30. Cristofano AD, Pandolfi PP. (2000) The multiple roles of PTEN in tumor suppression. Cell 100:387–390

    Article  PubMed  Google Scholar 

  31. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, Thurnher M, Bartsch G, Klocker H (1996) Regulation of prostatic growth and function by peptide growth factors. Prostate 28:392–405

    Article  PubMed  CAS  Google Scholar 

  32. Cunningham JM, Shan A, Wick MJ, McDonnell SK, Schaid DJ, Tester DJ, Qian J, Takahashi S, Jenkins RB, Bostwick DG, Thibodeau SN. (1996) Allelic imbalance and microsatellite instability in prostate adenocarcinoma. Cancer Res 56:4475–4482

    PubMed  CAS  Google Scholar 

  33. Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R (1992) Genetic variation at five rimeric and tetrameric tandem repeat loci in four human population groups. Genomics 12:241–253

    Article  PubMed  CAS  Google Scholar 

  34. Emmert-Buck M, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, Zhuang Z, Bostwick DG, Liotta LA, Linehan WM. (1995) Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 55:2959–2962

    PubMed  CAS  Google Scholar 

  35. Fair WR, Israeli RS, Heston WD. (1997) Prostate-specific membrane antigen. Prostate 32:140–148

    Article  PubMed  CAS  Google Scholar 

  36. Fearon ER. (1997) Human cancer syndromes: clues to the origin and nature of cancer. Science 278:1043–1050

    Article  PubMed  CAS  Google Scholar 

  37. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S (1994) Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancer. Cancer Res 54:2861–2864

    PubMed  CAS  Google Scholar 

  38. Gao CL, Dean RC, Pinto A, Mooneyhan R, Connelly RR, McLeod DG, Srivastava S, Moul JW. (1999) Detection of circulating PSA-expressing prostatic cells in bone marrow of radical prostatectomy patients by sensitive reverse transcriptase-polymerase chain reaction (RT-PCR). J Urol 161:1070–1076

    Article  PubMed  CAS  Google Scholar 

  39. Garnick MB, Fair WR. (1998) Combating prostate cancer. Sci Am 279:74–83

    Article  PubMed  CAS  Google Scholar 

  40. Gibbs M, Stanford JL, Mcindoe TA, Jarvik GP, Kolb S, Goode El, Chakrabarti L, et al (1999) Evidence for a rare prostate cancer-susceptibility locus at chromosome ip36. Am J Hum Genet 64:776–787

    Article  PubMed  CAS  Google Scholar 

  41. Giovannucci E, Stampfer MJ, Kiothivas K, Brown M, Brufsky A, Talcott J, Hennekens CH, Kantoff PH. (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci 94:3320–3323

    Article  PubMed  CAS  Google Scholar 

  42. Giroldi LA, Schalken JA. (1993) Decreased expression of the intercellular adhesion molecule E. cadherin in prostate cancer: biological significance and implications. Cancer Metastasis Rev 12:29–37

    Article  PubMed  CAS  Google Scholar 

  43. Grandori C, Eisenman RN. (1997) myc target genes. Trends Biochem Sci 22:177–181

    Article  PubMed  CAS  Google Scholar 

  44. Greenblatt MS, Bennett, WP, Hollstein M, Harris CC. (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855–4878

    PubMed  CAS  Google Scholar 

  45. Hakimi JM, Rondinelli RH, Schoenberg MP, Barrack ER. (1996) Androgen receptor gene structure and function in prostate cancer. World J Urol 14:329–337

    Article  PubMed  CAS  Google Scholar 

  46. Han G, Foster BA, Mistry S, Buchanan G, Harris JM, Tilley WD, Greenberg NM. (2000) Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem 10:1074

    Google Scholar 

  47. Harris CC. (1996) Structure and function of p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88:1442–1455

    Article  PubMed  CAS  Google Scholar 

  48. Harris CC, Hollstein M (1993) Clinical implications of the p53 tumor suppressor gene. N Engl J Med 329:1318–1327

    Article  PubMed  CAS  Google Scholar 

  49. Hartwell LH, Kastan MD. (1994) Cell cycle control and cancer. Science 266:1821–1828

    Article  PubMed  CAS  Google Scholar 

  50. Heidenberg HB, Sesterhenn IA, Gaddipati P, Weghorst CM, Buzard GS, Moul JW, Srivastava S (1995) Alterations of the tumor suppressor gene p53 in a high fraction of treatment resistant prostate cancer. J Urol 154:414–421

    Article  PubMed  CAS  Google Scholar 

  51. Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, Srivastava S (1996) The role of p53 tumor suppressor gene in prostate cancer: a possible biomarker? Urology 48:971–979

    Article  PubMed  CAS  Google Scholar 

  52. Henke RP, Kruger E, Ayhan N, Hubner D, Hammerer P, Huland H (1994) Immunohistochemical detection of p53 protein in human prostatic cancer. J Urol 152:1296–1301

    Google Scholar 

  53. Hermeking H, Lengauer C, Polyak K, He T-C, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B. (1997) 14–3–3α is a p53 regulated inhibitor of G2 M progression. Mol Cell 1:3–11

    Article  PubMed  CAS  Google Scholar 

  54. Hubert RS, Vivanco I, Chen E, Rastagar S, Leong K, Mitchell SC, Madraswala R, Zhou Y, Ku J, Raitano AB, Jakobovits A, Saffran DC, Afar DE. (1999) STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci USA 96:14523–14528

    Article  PubMed  CAS  Google Scholar 

  55. Huggins C, Hodges CV. (1941) Studies on prostatic cancer, effects of castration, of estrogens and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1:293–297

    CAS  Google Scholar 

  56. Ichikawa T, Nihei N, Suzuki H, Oshimura M, Emi M, Nakamura Y, Hayata I, Isaacs JT, Shimazaki J (1994) Suppression of metastasis of rat prostatic cancer by introducing human chromosome 8. Cancer Res 54:2299–2302

    PubMed  CAS  Google Scholar 

  57. Issacs SD, Kimeney LALM, Baffoe-Bonnie A, Bety TH, Walsh PC. (1995) Risk of cancer in relatives of prostate cancer probands. J Natl Cancer Inst 87:991–996

    Article  Google Scholar 

  58. Issacs WB, Bova GS. (1998) Prostate cancer. In: Vogelstein B, Kinzler KW. (eds) The genetic basis of human cancer. McGraw-Hill, New York, pp 653–660

    Google Scholar 

  59. Ittman M, Wieczorek R, Helle P, Dave A, Provet J, Krolewski J (1994) Alterations in the P53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Am J Pathol 145:287–293

    Google Scholar 

  60. Jenkins RB, Qian J, Lieber MM, Bostwick DG. (1997) Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57:524–531

    PubMed  CAS  Google Scholar 

  61. Kawakami M, Okaneya T, Furihata K, Nishizawa O, Katsuyama T (1997) Detection of prostate cancer cells circulating in peripheral blood by reverse transcription-PCR for hKLK2. Cancer Res 57:4167–4170

    PubMed  CAS  Google Scholar 

  62. Kazemi-Esfarjani P, Trifiro MA, Pinsky L (1995) Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n expanded neuronopathies. Hum Mol Genet 4:523–527

    Article  PubMed  CAS  Google Scholar 

  63. King CR, Kruas MH, Aaronson SA. (1985) Amplification of a novel c-erbB related gene in a human mammary carcinoma. Science 229:974

    Article  PubMed  CAS  Google Scholar 

  64. Ko SC, Gotoh A, Thalmann GN, Zhau HE, Jhonston DA, Zhang WW, Kao C, Chung LW. (1996) Molecular therapy with recombinant p53 adenovirus in androgen independent metastatic human prostate cancer model. Hum Gene Ther 7:1683–1691

    Article  PubMed  CAS  Google Scholar 

  65. Korsmeyer SJ. (1996) Molecular thanatopsis: discourse on the bcl-2 family and cell death. Blood 88:386–401

    PubMed  Google Scholar 

  66. Krajewska M, Krajewska S, Epstein JL, Shabaik A, Sauvagest J, Song K, Kitada S, Reed C (1996) Immunohistochemical analysis of bcl-2, bax, bcl-x and mcl-1 expression in prostate cancer. Am J Pathol 148:1567–1576

    PubMed  CAS  Google Scholar 

  67. Kubota Y, Fujinamic K, Uemura H, Dobashi Y, Miyamoto H, Iwasaki Y, Kitamura H, Shuin T (1995) Retinoblastoma gene mutations in primary human prostate cancer. Prostate 27:314–320

    Article  PubMed  CAS  Google Scholar 

  68. Kuhn EJ, Kurnot RA, Sesterhenn IA, Chang EH, Moul JW. (1993) Expression of the c-erbB-2 (HER-2 neu) oncoprotein in human prostatic carcinoma: prognostic determinants? J Urol 150:1427–1433

    PubMed  CAS  Google Scholar 

  69. Lalani E-N, Laniado ME, Abel PD. (1997) Molecular and cellular biology of prostate cancer. Cancer Metastasis Rev 16:29–66

    Article  Google Scholar 

  70. Levine A (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323–331

    Article  PubMed  CAS  Google Scholar 

  71. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Itterman M, Tycko B, Hibshoosh H, Wigler MH, Parsons R (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275:1943–1947

    Article  PubMed  CAS  Google Scholar 

  72. Liu AY, Corey E, Bladou F, Lange PH, Vessella RL. (1996) Prostatic cell lineage markers: emergence of bcl-2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Int J Cancer 65:85–89

    Article  PubMed  CAS  Google Scholar 

  73. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. (1993) An assessment of radical prostatectomy. Time trends, geographical variations and outcomes. JAMA 269:2633–2636

    Article  PubMed  CAS  Google Scholar 

  74. Macoska JA, Trybus TM, Benson PD, Sakr WA, Grignon DJ, Wojno KD, Pietruk T, Powell IJ. (1995) Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. Cancer Res 55:5390–5395

    PubMed  CAS  Google Scholar 

  75. Maguire HC, Greene MI. (1989) The neu (c-erbB-2) oncogene. Semin Oncol 16:148

    PubMed  CAS  Google Scholar 

  76. Marengo SR, Sikes RA, Anezinis P, Chang SM, Chung LW. (1997) Metastasis induced by overexpression of pi85 neu-T after orthotopic injection into a prostatic epithelial cell line (NbE). Mol Carcinog 19:165–175

    Article  PubMed  CAS  Google Scholar 

  77. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. (1992) Expression of proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:1940–1944

    Google Scholar 

  78. Mclndoe RA, Stanford JL, Gibbs M, Jarvik GP, Brandzel S, Neal CL, Li S, Gammack JT, Gay AA, Goode EL, Hood L, Ostrander EA. (1997) Linkage analysis of 49 high-risk families does not support a common familial prostate cancer susceptibility gene at 1q24-25. Am J Hum Genet 61:347–353

    Article  Google Scholar 

  79. Mellon K, Thompson S, Charlton RG, et al (1992) P53, c-erb-Bi and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 147:496–499

    PubMed  CAS  Google Scholar 

  80. Mostofi FK. (1975) Grading of prostate carcinoma. Cancer Chemother Rep 59:111

    PubMed  CAS  Google Scholar 

  81. Moul JW. (1997) Increased risk of prostate cancer in African American men. Mol Urol 1:119–127

    Google Scholar 

  82. Moul JW, Gaddipati J, Srivastava S (1994) Molecular biology of prostate cancer. Oncogene and tumor suppressor genes. In: Dawson NA, Vogelzang NJ. (eds) Current clinical oncology: prostate cancer. Wiley-Liss, pp 19–46

    Google Scholar 

  83. Moul JW, Bettencourt M-C, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Bauer JJ. (1996) Protein expression of p53, bcl-2 and KI-67 (MIB-i) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 120:159–167

    Article  PubMed  CAS  Google Scholar 

  84. Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL. (1999) Infusion of endritic cells pulsed with HLA-A2-specific prostate specific membrane antigen peptides: a phase 11 prostate cancer vaccine trail involving patients with hormone-refractory metastatic disease. Prostate 38:73–88

    Article  PubMed  CAS  Google Scholar 

  85. Myers RB, Brown D, Oelschlager DK, Waterbor JW, Marshall ME, Srivastava S, Stockard CR, Urban DA, Grizzle WE. (1996) Elevated serum levels of pi05 (c-erbB-2 in patients with advanced-stage prostatic adenocarcinoma. Int J Cancer 69:398–402

    Article  PubMed  CAS  Google Scholar 

  86. Newsham IF, Hadjistilianou T, Cavenee WK. (1998) Retinoblastoma. In: Vogelstein B, Kinzler K (eds) The genetic basis of human cancer. McGraw-Hill, New York, pp 363–392

    Google Scholar 

  87. Park M (1998) Oncogenes. In: Vogelstein B, Kinzler K (eds) The genetic basis of human cancer. McGraw-Hill, pp 205–228

    Google Scholar 

  88. Parker SL, Tong T, Bolden S, Wingo PA. (1996) Cancer statistics. CA Cancer J Clin 46:5–27

    Article  PubMed  CAS  Google Scholar 

  89. Partin AW, Oesterling JE. (1994) The clinical usefulness of prostate-specific antigen: update 1994. J Urol 152:1358–1368

    PubMed  CAS  Google Scholar 

  90. Phillips SM, Barton CM, Lee SJ, Morton DG, Wallace DM, Lemoine NR, Neoptolemos JP. (1994) Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostate tumorigenesis. Br J Cancer 70:1252–1257

    Article  PubMed  CAS  Google Scholar 

  91. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R (1995) Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen ablation in vivo. Cancer Res 55:4438–4445

    Google Scholar 

  92. Reiter ER, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, LeBeau MM, Loda M (1998) Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 95:1735–1740

    Article  PubMed  CAS  Google Scholar 

  93. Ross JS, Sheehan CE, Haynor-Buchan AM, Ambros RA, Kallakury BV, Kauffman RP, Fisher HA, Muraca PJ. (1997) HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Human Pathol 28:827–833

    Article  CAS  Google Scholar 

  94. Ross JS, Sheehan CE, Haynor-Buchan AM, Ambros RA, Kallakury BV, Kauffman RP, Fisher HA, Rifkin, MD, Muraca PJ. (1997) Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 79:162–170

    Article  Google Scholar 

  95. Sadasivan R, Morgan R, Jennings S, Austenfeld M, Van Veldhuizen P, Stephens R, Noble M (1993) Overexpression of HER-2/neu may be an indicator of poor prognosis in prostate cancer. J Urol 150:126–131

    PubMed  CAS  Google Scholar 

  96. Schoenberg MP, Hakimi JM, Wang S, Bova GS, Epstein JI, Fischbeck KH, Isaacs WB, Walsh PC, Barrack ER. (1994) Microsatellite mutation (CAG24-18 ) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun 198:74–80

    Article  PubMed  CAS  Google Scholar 

  97. Semba K, Kamata N, Toyoshima K, et al (1985) A V-erb related proto-oncogene, c-erbB-2 is distinct from the c-erbB-1 epidermal growth factor receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci 82:6497

    Article  PubMed  CAS  Google Scholar 

  98. Shi XB, Gumerlock PH, deVere White RW. (1996) Molecular biology of prostate cancer. World J Urol 14:318–328

    Article  PubMed  CAS  Google Scholar 

  99. Smith JR, Freije D, Carpten JD, Gronberg H, et al (1996) Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 276:1371–1374

    Article  Google Scholar 

  100. Srikantan V, Sesterhenn IA. Davis L, Hankins GR, Avellone FA, Livezey JR, Connelly R, Mostofi FK, McLeod DG, Moul JW, Chandrasekha rappa S, Srivastava S (1999) Allelic loss on chromosome 6q in primary prostate cancer. Int J Cancer 84:331–335

    Article  PubMed  CAS  Google Scholar 

  101. Srikantan V, Zou Z, Petrovics G, Xu LL, Augustus M, Davis L, Livezey JR, Connell T, Sesterhenn IA, Yoshino K, Buzard GS, Mostofi FK, McLeod DG, Moul JW, Srivastava S (2000) PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci 97:12216–12221

    Article  PubMed  CAS  Google Scholar 

  102. Srivastava S, Katayose D, Tong YA, Craig CR, McLeod DG, Moul JW, Cowan K, Seth P (1995) Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation. Urology 46:843–848

    Article  PubMed  CAS  Google Scholar 

  103. Stapleton AMF, Timme TL, Gousse AE, Li Q-F, Tobon AA, Kattan MW, Slawin KM, Wheeler TM, Scardino PT, Thompson TC. (1997) Primary prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 3:1389–1397

    PubMed  CAS  Google Scholar 

  104. Steck PA, Pershouse MA, Jasser SA, Yung WAK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DHF, Tavtigian SV. (1997) Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356–362

    Article  PubMed  CAS  Google Scholar 

  105. Strieker HJ, Jay JK, Linder MD, Tamboli P, Amin MB. (1996) Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. Urology 47:366–369

    Article  Google Scholar 

  106. Suzuki H, Sato N, Watabe Y, Msai M, Seino S, Shimazaki J (1993) Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 46:759–765

    Article  PubMed  CAS  Google Scholar 

  107. Suzuki H, Koichiro A, Komiya A, Aida S, Akimoato S, Shimazaki J (1996) Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 29:153–158

    Article  PubMed  CAS  Google Scholar 

  108. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB, Bova GS. (1998) Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 58:204–209

    PubMed  CAS  Google Scholar 

  109. Taiguchi J, Moriyama N, Kasimoto S, Kameyama S, Kawabe K (1996) Histochemical detection of intranuclear DNA fragmentation and its relation to the expression of bcl-2 oncoprotein in human prostate cancer. Br J Urol 74:719–723

    Google Scholar 

  110. Tavtigian SV, Simard J, Teng DHF, Abtin V, Baumgard M, et al (2001) A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 27:172–180

    Article  PubMed  CAS  Google Scholar 

  111. Tilley WD, Buchanan G, Hickey TE, Bentel JM. (1996) Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2:277–285

    PubMed  CAS  Google Scholar 

  112. Trapman J, Sleddens HF, van der Weiden MM, Dinjens WN, Koing JJ, Schroder FH, Faber PW, Bosman FT. (1994) Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res 54:6061–6064

    PubMed  CAS  Google Scholar 

  113. Van Veldhuizen PJ, Sadasivan R, Garcia F, Austenfield MD, Stephens RL. (1993) Mutant p53 expression in prostate carcinoma. Prostate 22:23–30

    Article  PubMed  Google Scholar 

  114. Visakorpi T, Kallioniemi OP, Koivula T, Harvey, J Isola J (1992) Expression of epidermal growth factor receptor and ERBB2 (HER-2/neu) oncoprotein in prostatic carcinomas. Mod Pathol 5:643–648

    PubMed  CAS  Google Scholar 

  115. Visakorpi T, Kallioniemi OP, Heikinen A, Koivula T, Isola J (1992) Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84:883–887

    Article  PubMed  CAS  Google Scholar 

  116. Visakorpi T, Kallioniemi OP, Koivula T, Isola J (1993) New prognostic factors in prostate carcinoma. Eur Urol 24:438–449

    PubMed  CAS  Google Scholar 

  117. Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, Duray PH, Liotta LA, Emmert-Buck MR, Linehan WM. (1996) Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p2i-22. Cancer Res 56:2411–2416

    PubMed  CAS  Google Scholar 

  118. Ware JL, Maygarden SJ, Koontz WW, Strom SC. (1991) Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. Hum Pathol 22:254

    Article  PubMed  CAS  Google Scholar 

  119. Wasson JH, Cushman CC, Bruskewit RC, Littenberg B, Mulley AG, Wennberg JE. (1993) A structured literature review of treatment for localized prostate cancer. Arch Fam Med 2:487–493

    Article  PubMed  CAS  Google Scholar 

  120. Weinberg RA. (1996) How cancer arises. Sci Am 9:62–70

    Article  Google Scholar 

  121. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC. (2000) Her-2/neo promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60:6841–6845

    PubMed  CAS  Google Scholar 

  122. Xu J, Meyers DA, Freije D, Issacs S, Wiley K, Nusskern D, Ewing C, et al (1998) Evidence for a prostate cancer susceptibility focus on the X chromosome. Nat Genet 20:175–179

    Article  PubMed  CAS  Google Scholar 

  123. Xu LL, Srikantan V, Sesterhenn IA, Augustus M, Dean R, Moul JW, Carter KC, Srivastava S (2000) Expression profile of an androgen-regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. J Urol 163:972–979

    Article  PubMed  CAS  Google Scholar 

  124. Xu LL, Stackhouse BG, Florence K, Zhang W, Shanmugam N, Sesterhenn IA, Zou Z, Srikantan V, Augustus M, Roschke V, Carter K, McLeod DG, Moul JW, Soppett D, Srivastava S (2000) PSGR, a novel prostate-specific gene with homology to a G-protein-coupled receptor, is overexpressed in prostate cancer. Cancer Res 60:6568–6572

    PubMed  CAS  Google Scholar 

  125. Yang G, Stapleton AMF, Wheeler TM, Truong LD, Timme TL, Scardino PT, Thompson TC. (1996) Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res 2:399–401

    PubMed  CAS  Google Scholar 

  126. Zhau HE, Wan DS, Zhou J, Miller GJ, Von Eschenbach AC. (1992) Expression of c-erbB-2/neu proto-oncogene in human prostatic cancer tissues and cell lines. Mol Carcinog 5:320–327

    Article  PubMed  CAS  Google Scholar 

  127. Zhau HY, Zhou J, Symmans WF, Chen BQ, Chang SM, Sikes RA, Chung LW. (1996) Transfected neu oncogene induces human prostate cancer metastasis. Prostate 28:73–83

    Article  PubMed  CAS  Google Scholar 

  128. Zhau HY, Chang SM, Chen BQ, Wang Y, Zhang H, Kao C, Sang QA, Chung LW. (1996) Androgen repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 93:15152–15157

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. V. Srikantan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Srivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology and Pediatric Urology, Philipps Universität Marburg, Baldingerstrasse 3, 35043, Marburg/Lahn, Germany

    Reiner Hofmann  & Axel Heidenreich  & 

  2. Department of Surgery, USUHS, 430 I Jones Bridge Road, 20814-4799, Bethesda, MD, USA

    Judd W. Moul M.D. (Professor of Urology) (Professor of Urology)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Srikantan, V., Srivastava, S. (2003). Molecular Dissection of the Prostate Cancer Genome. In: Hofmann, R., Heidenreich, A., Moul, J.W. (eds) Prostate Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56321-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56321-8_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62643-2

  • Online ISBN: 978-3-642-56321-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation